Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO.
Xin MaMeng TianXueping YuMing LiuBin LiDayong RenWei WangPublished in: Foods (Basel, Switzerland) (2024)
In addition to providing certain health advantages to the host, a bacterial strain must possess a clearly defined safety profile to be regarded as a probiotic. In this study, we present a thorough and methodical assessment of the safety of a novel strain of bacteria, Akkermansia muciniphila PROBIO, which was isolated from human feces. Firstly, we examined the strain's overall features, such as its gastrointestinal tolerance and its physiological and biochemical traits. Next, we verified its genotoxic properties through bacterial reverse mutation and in vitro mammalian cell micronucleus assays. The drug sensitivity of A. muciniphila PROBIO was subsequently examined through an analysis of its antibiotic resistance genes. Additionally, the toxicological impact was verified through acute and sub-chronic toxicity studies. A genome-based safety assessment was conducted to gain further insights into gene function, including potential virulence factors and pathogenic properties. Finally, we assessed whether moxifloxacin resistance in A. muciniphila PROBIO is transferred using in vitro conjugation experiments. A. muciniphila PROBIO exhibited superior gastrointestinal tolerance, with no observed hematological or histopathological abnormalities. Moreover, the outcomes pertaining to mutagenic, clastogenic, or toxic impacts were found to be negative, even at exceedingly high dosages. Moreover, no adverse effects associated with the test substance were observed during the examination of acute and sub-chronic toxicity. Consequently, it was plausible to estimate the no-observed-adverse-effect level (NOAEL) to be 6.4 × 10 11 viable bacteria for an average individual weighing 70 kg. Additionally, only three potential drug resistance genes and one virulence factor gene were annotated. A. muciniphila PROBIO is naturally resistant to moxifloxacin, and resistance does not transfer. Collectively, the data presented herein substantiate the presumed safety of A. muciniphila PROBIO for its application in food.
Keyphrases
- genome wide
- antibiotic resistance genes
- drug induced
- liver failure
- staphylococcus aureus
- escherichia coli
- pseudomonas aeruginosa
- healthcare
- antimicrobial resistance
- endothelial cells
- oxidative stress
- respiratory failure
- wastewater treatment
- human health
- copy number
- dna methylation
- metabolic syndrome
- biofilm formation
- type diabetes
- risk assessment
- stem cells
- cystic fibrosis
- intensive care unit
- aortic dissection
- cell therapy
- mesenchymal stem cells
- bone marrow
- oxide nanoparticles
- insulin resistance
- deep learning
- case control
- acute respiratory distress syndrome